|Task Force on Anti-Terrorism & Public Security
Task Force on Anti-Terrorism & Public Security
resources - press releases - home
Ronald C. Kennedy
Dr. Kennedy has received a number of awards and honors including the Chairman of the San Antonio City Council HIV/AIDS Commission, an Advisor to the City of San Antonio, a Citation for Outstanding Service to the Community by the City of San Antonio, an Honorary Director of Kumamoto City Hospital, Japan, and a Provost Senior Research Award from the University of Oklahoma. He has also served on a number of Federal Committees and Panels for the NIH, the Department of Defense, and the National Academy of Sciences.
Dr. Kennedy has received over $25 million dollars in Federal support for his research activities and his work is presently supported by the NIH. His areas of research interests include HIV infection and AIDS, cancer, hepatitis viruses and maternal-fetal medicine. This research focuses of vaccines and immunology with an interest on mechanism(s) of protective immunity. He has over 200 scientific publications in such journals as Science, Nature Medicine, Cell, and Scientific American. He has been an invited speaker and Chairperson in a number of National and International Scientific Symposia and Meetings and has testified before members of the U.S. Congress on issues related to vaccine safety. Dr. Kennedy has trained a number of undergraduate, graduate, medical students and physicians with regards to research related activities who have attained positions in both the Pharmaceutical Industry and in Academia. He serves on a number of Scientific Journal Editorial Boards and has edited several Scientific Books. His research involves working with emerging infectious disease agents that represent BioSafety Level (BSL) 3 and 4 containment pathogens. He has experience in working in these containment facilities and was involved in the construction and as the Director of the BSL3 facility at the University of Oklahoma. His work also includes the development of models to test and evaluate vaccines and treatments for these emerging infectious agents that are relevant to the human situation.
|Copyright 2001 Texas Tech University
TTU Compliance with the Digital Millennium Copyright Act